TTRX TTRX Share-Based Payment Award Options Outstanding - Number

Share-Based Payment Award Options Outstanding - Number at other companies

PTH

Pelthos Therapeutics Inc.PTHS

1.5M+1,668%

Arcutis Biotherapeutics, Inc.ARQT

7.6M+9.2%

Tarsus Pharmaceuticals, Inc.TARS

5.6M+5.2%

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Operating cash flow-$1.6M-448%

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is TTRX's share-based payment award options outstanding - number?: TTRX (TTRX) reported share-based payment award options outstanding - number of $1.94M in Q1 2026.
What does share-based payment award options outstanding - number mean?: This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.